Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes

Status Withdrawn

Clinical Trial Summary

Ivabradine, a selective inhibitor of the If current in the sinoatrial node, provides heart rate reduction and leads to a reduction in heart failure hospitalizations. For this reason, the American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines provide a class IIa recommendation for ivabradine in stable heart failure patients with LVEF 35% and New York Heart Association (NYHA) class II-III symptoms who are on a beta blocker at maximum tolerated dose with a resting heart rate of 70 beats per minute or greater. While ivabradine leads to improvement in outcomes in stable NYHA class II-III chronic heart failure patients, its role in class IV, stage D heart failure, and cardiogenic shock is less clear. Ivabradine's effect on acute cardiogenic shock has been evaluated by two recent studies. In the MODIFY trial, a randomized control study evaluating ivabradine in patients with multiorgan dysfunction, the addition of ivabradine did not result in significant heart rate reductions or other positive clinical outcomes. However, a small prospective trial demonstrated a significant decrease in heart rate and NT-proBNP with the addition of ivabradine in patients with acute cardiogenic shock on dobutamine. While few data investigate ivabradine's role in acute cardiogenic shock, it has yet to be studied in heart failure patients on long-term inotropic therapy. Inotropes such as dobutamine and milrinone result in tachycardia and may lead to ventricular arrhythmias. Moreover, patients on chronic inotropes are typically off beta blockers and have few pharmacological options available to help reduce heart rates. Ivabradine may have a role in decreasing heart rate and improving outcomes in patients on chronic inotropes. Given the benefits of ivabradine in stable chronic heart failure patients, we plan to perform a study investigating the role of ivabradine in NYHA Stage D patients on home inotropes. Our primary objective is to analyze changes in two cardiac biomarkers, NT-proBNP and high-sensitivity troponin. Our secondary outcomes include changes in noninvasive echocardiographic hemodynamics, changes in arrhythmia burden, and heart failure symptom modification based on 6-minute walk test results.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03631654
Study type	Interventional
Source	University of Maryland, Baltimore
Contact
Status	Withdrawn
Phase	Phase 4
Start date	October 1, 2020
Completion date	August 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04528004` - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure	Early Phase 1
Not yet recruiting	`NCT06097481` - Narrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF)	Phase 1/Phase 2
Not yet recruiting	`NCT01669395` - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial	N/A
Completed	`NCT05835063` - A Study to Improve Physician-Youth Communication and Medical Decision Making	N/A
Completed	`NCT03895073` - HEart fAiluRe evaluaTion Questionnaire
Completed	`NCT06233695` - Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Recruiting	`NCT04237701` - Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
Withdrawn	`NCT03947853` - Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) in Patients With Symptomatic Heart Failure
Recruiting	`NCT05487365` - Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support in Patients With HF	N/A
Completed	`NCT03592836` - Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion	Phase 3
Completed	`NCT03387813` - Hemodynamic-GUIDEd Management of Heart Failure	N/A
Completed	`NCT03580759` - Exergaming in Advanced HF With Multiple Chronic Conditions Prior to LVAD Implantation or Heart Transplant	N/A
Not yet recruiting	`NCT06270875` - Addressing Pain Through Navigator-Led Palliative Care Optimized for Heart Failure (ADAPT-HF)	N/A
Recruiting	`NCT05879887` - An Optimization Pilot to Optimize An Early Palliative Care Intervention for Advanced Heart Failure	N/A
Completed	`NCT04180696` - Mid-Q Response Study	N/A
Recruiting	`NCT01774656` - Remission From Stage D Heart Failure	Phase 4
Active, not recruiting	`NCT02880358` - Epidemiology and Prognostic of the Acute Heart Failure	N/A
Completed	`NCT04153890` - Family Palliative and End-of-Life Care for Advanced Heart Failure	N/A
Completed	`NCT04218435` - Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients
Recruiting	`NCT05647213` - Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.